HomeTerms of Use

Terms of Use

The information contained herein is not intended to constitute medical or health care advice or to be used for medical diagnosis or treatment.  Yodeah assumes no responsibility for any consequence relating to any action or inaction you take based upon the information or materials on this website.  Always consult a qualified health care professional regarding any medical condition.  If you have health-related questions, contact your health care provider promptly. Never disregard medical advice or delay in seeking it because of something you have read here. 

Information contained herein is a summary only and provides only a broad understanding and knowledge of the topics.  The information should not be considered complete or used in place of a consultation or advice of your physician or other health care provider.  Yodeah is not responsible for any damage or loss related to the accuracy, completeness, or timeliness of the information provided on this website and assumes no responsibility to update or keep information current.

Yodeah may provide links to other websites. When you enter these other websites, you are entering websites for which Yodeah has no responsibility.   We do not guarantee the accuracy of information on these websites and do not endorse the information or services contained on or accessible through these websites.  We recommend you read the Privacy and Disclaimer notices which may differ from ours.

You assume full responsibility for using information on this website and agree that Yodeah is not responsible or liable for any claim, loss or damage resulting from any use of information on this website.  In other words, you waive any claims against Yodeah.  By accessing the Yodeah website, you are acknowledging that you have read these Terms of Use and agree to the terms and conditions set forth herein, including waiving any claim, for any reason whatsoever, against Yodeah.  

THE MOST RELEVANT GENES FOR COMMON HEREDITARY CANCERS

* CDK4: analysis is limited to chr12:g.58145429-58145431 (codon 24). EPCAM: analysis is limited to deletions that minimally encompass the 3′ end of the gene including exons 8 and/or 9. GREM1: analysis is limited to duplications that overlap the upstream regulatory region. MITF: analysis is limited to chr3:g.70014091 (including c.952G>A). MUTYH: single heterozygous pathogenic variants, likely pathogenic variants, and variants of uncertain significance are not reported. PMS2: variants of uncertain significance are not reported for exons 12-15. Analysis excludes three variants commonly observed in the pseudogene PMS2CL: c.2182_2184delinsG, c.2243_2246delAGAA and deletion of exons 13-14 (chr7:g.6015768_6018727del). POLD1: analysis is limited to chr19:g.50909713 (including c.1433G>A). POLE: analysis is limited to chr12:g.133250250 (including c.1270C>G).